Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.

Blood reviews - 1 Jan 2016

Lee Eun-Ju, Podoltsev Nikolai, Gore Steven D, Zeidan Amer M

Abstract excerpt

The clinical course of patients with myelodysplastic syndromes (MDS) is characterized by wide variability reflecting the underlying genetic and biological heterogeneity of the disease. Accurate prediction of outcomes for individual patients is an integral part of the evidence-based risk/benefit calculations that are necessary for tailoring the aggressiveness of therapeutic interventions. While several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 7

Share to Disease Management

Share to Myelodysplastic Syndromes

Share to Precision Medicine

Share to Research Design

Share to Survival Analysis

Source

Identifiers

PMID: 26119927
DOI: 10.1016/j.blre.2015.06.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.PMID 26119927Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Semantic proximity Read ↗

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

Clinical and genetic predictors of prognosis in myelodysplastic syndromesSemantic proximity Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

Does mutational burden add to other prognostic factors in MDS?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.